← Back to Clinical Trials
Recruiting Phase 4 NCT04119102

NCT04119102 Duobrii in Combination With Biologics

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT04119102
Status Recruiting
Phase Phase 4
Sponsor Psoriasis Treatment Center of Central New Jersey
Condition Psoriasis
Study Type INTERVENTIONAL
Enrollment 25 participants
Start Date 2019-10-14
Primary Completion 2020-08-01

Eligibility & Interventions

Sex All sexes
Min Age 18 Years
Max Age N/A
Study Type INTERVENTIONAL
Interventions
Duobrii

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

Phase 4 studies follow an already-approved treatment in real-world conditions to monitor long-term safety and effectiveness.

This trial targets 25 participants in total. It began in 2019-10-14 with a primary completion date of 2020-08-01.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

12 weeks DUOBRII to patients with 2%-10% BSA who are receiving biologic therapy for at least 24 weeks

Eligibility Criteria

Inclusion Criteria: 1. Male or female adult ≥ 18 years of age; 2. Diagnosis of chronic plaque-type 3. Psoriasis affecting 2%-10% BSA 4. Patient is being treated with biologic therapy for a minimum of 24 weeks 5. Able and willing to give written informed consent prior to performance of any study-related procedures Exclusion Criteria: 1. Psoriasis affecting ˂2% or \>10% BSA 2. Patient not receiving a biologic agent, or receiving biologic agent \<24weeks 3. Received treatment with any topical antipsoriatic drug product within 14 days prior to the Baseline visit. 4. Has previously used DUOBRII

Contact & Investigator

Central Contact

Jerry Bagel, MD

✉ dreamacres1@aol.com

📞 6094434500

Frequently Asked Questions

Who can join the NCT04119102 clinical trial?

This trial is open to participants of all sexes, aged 18 Years or older, studying Psoriasis. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

What phase is the NCT04119102 trial and what does that mean for participants?

Phase 4 studies are conducted after a treatment has been approved. They monitor long-term safety and real-world effectiveness in a broader patient population.

Is NCT04119102 currently recruiting?

Yes, NCT04119102 is actively recruiting participants. Contact the research team at dreamacres1@aol.com for enrollment information.

Where is the NCT04119102 trial being conducted?

This trial is being conducted at East Windsor, United States.

Who is sponsoring the NCT04119102 clinical trial?

NCT04119102 is sponsored by Psoriasis Treatment Center of Central New Jersey. The trial plans to enroll 25 participants.

Related Trials

Related Intelligence Guides

In-depth guides covering this condition's trials, eligibility, and what to expect.

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: September 2026  ·  Data Methodology